General Information of Drug (ID: DMD3AJH)

Drug Name
Linear peptide of RES-701-1 Drug Info
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
77282233
TTD Drug ID
DMD3AJH

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Discontinued Drug(s)
Preclinical Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Bosentan DMIOGBU Pulmonary arterial hypertension BB01.0 Approved [2]
Macitentan DMP79A1 Cardiovascular disease BA00-BE2Z Approved [3]
BQ788 DM6KRLW Acute kidney injury GB60 Phase 3 [4]
PD-145065 DMWVBTQ Hypertension BA00-BA04 Phase 2 [5]
SPI-1620 DMNPRMC Solid tumour/cancer 2A00-2F9Z Phase 2 [6]
ENB003 DMK2B3S Melanoma 2C30 Phase 1/2 [7]
J-104132 DM5E6MK Pulmonary arterial hypertension BB01.0 Discontinued in Phase 2 [8]
ENRASENTAN DM05F1Z Pulmonary arterial hypertension BB01.0 Discontinued in Phase 2 [9]
SB-209670 DMJYW80 Arrhythmia BC9Z Discontinued in Phase 2 [10]
ET-1 DMA85ND N. A. N. A. Phase 0 [11]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Endothelin B receptor (EDNRB) TT3ZTGU EDNRB_HUMAN Inhibitor [1]

References

1 RES-701-1/endothelin-1 hybrid peptide having a potent binding activity for type B receptor, Bioorg. Med. Chem. Lett. 7(13):1715-1720 (1997).
2 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
3 Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
4 BQ788, an endothelin ET(B) receptor antagonist, attenuates stab wound injury-induced reactive astrocytes in rat brain. Glia. 1999 May;26(3):268-71.
5 Reversal of established responses to endothelin-1 in vivo and in vitro by the endothelin receptor antagonists, BQ-123 and PD 145065. Br J Pharmacol. 1994 May;112(1):207-13.
6 Clinical pipeline report, company report or official report of Spectrum Phamaceuticals (2009).
7 ClinicalTrials.gov (NCT04205227) A Phase 1/2A Trial of ENB 003 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors. U.S.National Institutes of Health.
8 Pharmacological properties of J-104132 (L-753,037), a potent, orally active, mixed ETA/ETB endothelin receptor antagonist. J Pharmacol Exp Ther. 1999 Jun;289(3):1262-70.
9 Enrasentan, an antagonist of endothelin receptors. Cardiovasc Drug Rev. 2003 Spring;21(1):1-16.
10 Effects of the endothelin receptor antagonist, SB 209670, on circulatory failure and organ injury in endotoxic shock in the anaesthetized rat. Br J Pharmacol. 1996 May;118(1):198-204.
11 IRL 2500: A potent ETB selective endothelin antagonist, Bioorg. Med. Chem. Lett. 6(19):2323-2328 (1996).